ANNEX: Continuous subcutaneous insulin infusion device eligible for subsidy

Company	Category	Model
Medtronic	Insulin Pump	MiniMed 700G System MiniMed Paradigm Veo 754 Insulin Pump[1]
	Infusion set	Quickset Infusion set (Needle Length: 6/9mm| Tubing length: 60 cm) Sure T infusion set (Needle Length: 6/8mm| Tubing length: 60 cm)
	Insulin Reservoir	MiniMed Reservoir 3mL
Roche	Insulin Pump	Accu-Chek Spirit Combo Insulin Pump[2] Accu-Chek Performa Combo Blood Glucose Meter
	Infusion set	Accu-Check FlexLink Infusion Set (Needle Length: 6/8/10 mm | Tubing length: 60 cm)
	Cannula	Accu-Chek FlexLink Cannula (Needle Length: 6/8/10 mm)
	Insulin Cartridge	Accu-Chek Spirit Insulin Cartridge 3.15 mL

The CSII listed in Annex are not affected by cybersecurity risk, where an unauthorised person with special technical skills and equipment could alter settings and control insulin delivery.

Note: *This Annex will be updated as CSII models are revised. Details on the model can be provided upon request.*

[1]Medtronic has notified that:

i. Supply for MiniMed Paradigm Veo 754 Insulin Pump will be discontinued and replaced with the MiniMed 700G System from 1 October 2022.

[2]Roche notified that:

ii. Supply of the Accu-Check Spirit Combo Insulin Pump and Accu-Chek Performa Combo Blood Glucose Meter will be discontinued from 1 February 2022.

iii. Existing patients with an active warranty for the aforementioned pump and glucose meter will continue to be supported.

iv. Support and supply for the Accu-Chek FlexLink infusion and cannula set and Accu-Chek Spirit insulin cartridge 3.15 mL will continue.

Last updated on 1 October 2022

About the Agency

The Agency for Care effectiveness (ACE) is the national health technology assessment agency in Singapore residing within the Ministry of Health. It conducts evaluations to inform the subsidy of treatments, and produces guidance on the appropriate use of treatments for public hospitals and institutions in Singapore. When using the guidance, the responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional. This guidance is based on the evidence available to the Committee as of 22 March 2019.This guidance is not, and should not be regarded as a substitute for, professional/medical advice. Please seek the advice of a qualified healthcare professional on any medical condition.

Find out more about ACE at www.ace-hta.gov.sg/about

Chief HTA Officer
Agency for Care Effectiveness
Email: ACE_HTA@moh.gov.sg